{"filing":{"accession_number":"0001193125-26-298005","cik":"0001609809","ticker":"MCRB","company_name":"Seres Therapeutics, Inc.","form":"8-K","filing_date":"2026-07-08","report_date":null,"primary_document":"d130829d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1609809/000119312526298005/d130829d8k.htm"},"events":[{"id":16606,"run_id":14838,"accession_number":"0001193125-26-298005","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.8,"summary":"Seres Therapeutics announced top-line clinical results from an investigator-sponsored trial of SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC), with 80% of participants achieving the primary endpoint of immunosuppressive-free clinical response at Day 15 and no drug-related serious adverse events. This material clinical development milestone was disclosed via press release and updated corporate presentation on July 8, 2026.","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-07-08","form":"8-K","submitted_at":null,"items":[{"id":14758,"accession_number":"0001193125-26-298005","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses top-line clinical results from an investigator-sponsored trial (IST) of SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC), announced via press release on July 8, 2026. While this is clinical trial data rather than financial earnings, it is disclosed under Item 7.01 (Regulation FD Disclosure) as a material corporate announcement with exhibits (press release and updated corporate presentation). The disclosure of positive clinical trial results—80% of participants achieved immunosuppressive-free clinical response at Day 15, with no drug-related serious adverse events—represents a significant milestone for a clinical-stage biotech company and would materially affect investor assessment of the registrant's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T12:01:42.086899+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14759,"accession_number":"0001193125-26-298005","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces top-line clinical trial results for SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC), showing 80% of participants achieved the primary endpoint of immunosuppressive-free clinical response at Day 15. While this is a clinical development milestone for a pipeline asset, it does not fit the specific \"earnings_release\" category (which typically refers to quarterly/annual financial results) nor any other defined event type. The event is clearly operational/strategic in nature—a material clinical development milestone that would affect investor assessment of the company's pipeline progress and commercial prospects, particularly given the company's focus on advancing SER-155 and seeking funding and partnerships.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T12:01:42.086899+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14758,"accession_number":"0001193125-26-298005","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.85,"reasoning":"The filing discloses top-line clinical results from an investigator-sponsored trial (IST) of SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC), announced via press release on July 8, 2026. While this is clinical trial data rather than financial earnings, it is disclosed under Item 7.01 (Regulation FD Disclosure) as a material corporate announcement with exhibits (press release and updated corporate presentation). The disclosure of positive clinical trial results—80% of participants achieved immunosuppressive-free clinical response at Day 15, with no drug-related serious adverse events—represents a significant milestone for a clinical-stage biotech company and would materially affect investor assessment of the registrant's pipeline and prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T12:01:42.086899+00:00","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-07-08"},{"id":14759,"accession_number":"0001193125-26-298005","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This disclosure announces top-line clinical trial results for SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC), showing 80% of participants achieved the primary endpoint of immunosuppressive-free clinical response at Day 15. While this is a clinical development milestone for a pipeline asset, it does not fit the specific \"earnings_release\" category (which typically refers to quarterly/annual financial results) nor any other defined event type. The event is clearly operational/strategic in nature—a material clinical development milestone that would affect investor assessment of the company's pipeline progress and commercial prospects, particularly given the company's focus on advancing SER-155 and seeking funding and partnerships.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-08T12:01:42.086899+00:00","company_name":"Seres Therapeutics, Inc.","ticker":"MCRB","filing_date":"2026-07-08"}]}